Children with Cystic Fibrosis Harbor a Colorectal Cancer Toxin in Their Gut

Children with cystic fibrosis develop colorectal cancer at roughly 10 times the rate of the general population, and the tumors often appear 20 to 30 years earlier than expected. Researchers have long suspected gut dysbiosis as the driver, but the specific microbial mechanisms have been murky. A new study published in the Journal of Bacteriology by Barrack KE et al. now points a finger at colibactin, a DNA-damaging genotoxin produced by certain strains of E. coli, and lays out a plausible chain of events linking the cystic fibrosis gut environment to that elevated cancer risk.

Colibactin-producing E. coli is more common in CF children's stool

The study's most striking epidemiological signal came from a large metagenomic dataset: 208 stool samples from children with cystic fibrosis and 2,560 from non-CF controls. Genes encoding colibactin biosynthesis, specifically clbB, were 2.38 times more prevalent in CF children's stool (P = 4.362e-07), and their abundance correlated directly with E. coli's relative abundance in those samples. That correlation matters because it suggests the extra E. coli colonizing the CF gut is not just any E. coli; it disproportionately carries the pks island, the 54-kilobase genetic cluster encoding the 19 clb genes that produce colibactin.

Colibactin works by deploying electrophilic cyclopropane warheads that alkylate DNA at adenine-rich sequences, causing interstrand cross-links. That mechanism is the same one researchers studying childhood exposure to colibactin as a trigger for early-onset colorectal cancer have identified in broader CRC epidemiology. In CF, the combination of more E. coli and a gut environment that promotes colibactin production may amplify that genotoxic pressure considerably.

Free glycerol in the CF gut fuels the genotoxin machinery

To understand why pks-positive E. coli might be especially active in the CF colon, the team used CF-MiPro, a culture medium designed to mimic the CF intestinal environment, including elevated fats, mucin, bile, reactive oxygen species, and sub-lethal antibiotic concentrations. When they co-cultured E. coli with Bacteroides vulgatus (recently renamed Phocaeicola vulgatus), a beneficial anaerobe consistently depleted in CF stool, they found that B. vulgatus viability dropped significantly within 8 hours, and the effect was dose-dependent.

Linear regression across the medium's components identified two variables driving B. vulgatus loss: bile and free glycerol. The glycerol finding is particularly consequential. Stool samples from children with CF contained 8-fold more free glycerol than non-CF controls (P = 7.4e-05), likely reflecting the malabsorption of dietary fats that is a hallmark of CF. In co-culture experiments, added glycerol pushed 50 percent of B. vulgatus strains below the detection limit. Critically, this effect required live E. coli cells, not cell-free supernatants, which argues for active microbial competition rather than a secreted toxin diffusing at a distance.

Transposon screen fingered the pks island as the key genetic player

To identify which E. coli genes drove B. vulgatus depletion, the team ran a transposon mutagenesis screen, systematically disrupting individual genes and testing whether the mutant still killed B. vulgatus in glycerol-supplemented co-culture. Mutants with insertions in clb genes, the colibactin biosynthesis cluster, lost their ability to suppress B. vulgatus. Genes tied to glycerol metabolism (dhaR, dhaK, dhaL, gldA) also appeared as hits, reinforcing the connection between glycerol availability and colibactin activity.

The researchers then confirmed the result two ways. A clbP null mutant, clbP encodes the periplasmic peptidase that cleaves the inactive precolibactin prodrug into active colibactin, reversed the suppression of B. vulgatus in the presence of glycerol. Chemical inhibition of ClbP produced the same rescue. Both glycerol supplementation and co-culture with B. vulgatus also independently increased measurable colibactin prodrug levels in E. coli cultures, suggesting microbial competition itself upregulates the pathway.

Key limitations of an early-stage in vitro study

These findings are preliminary and carry real caveats. Every experiment was conducted in liquid culture, not in an intact gut with its spatial structure, mucus layers, and immune signaling. Only four bacterial species were tested, so conclusions about broader community dynamics are speculative. The glycerol concentrations used may exceed what CF children actually experience in their colons, and the study lacked dietary metadata to calibrate that question. Most importantly, colibactin itself is extraordinarily unstable; measuring its prodrug metabolite and inferring genotoxic activity in vivo are not the same as measuring actual DNA damage in colonocytes. The metagenomic clbB signal establishes prevalence, not confirmed enzymatic activity.

None of that makes the findings unimportant. It means they need in vivo validation before anyone draws clinical conclusions.

Screening CF infants for pks-positive E. coli as a next step

The authors suggest that screening CF infants for pks-positive E. coli could become a practical early-warning tool for dysbiosis and long-term CRC risk. If the colibactin-B. vulgatus competition axis holds up in animal models or organoid studies, it would also open a specific therapeutic target: blocking ClbP enzymatic activity could, in principle, disarm the genotoxin without eliminating E. coli entirely.

Broader microbiome-level strategies, including probiotics, prebiotics, and dietary interventions aimed at reducing free glycerol availability, are already being explored for gut microbiota modulation as a CRC prevention approach. For CF specifically, CFTR modulators that restore epithelial physiology and improve mucus hydration may partially reset the gut environment before dysbiosis becomes entrenched. Whether any of these approaches can meaningfully reduce colibactin production or protect B. vulgatus populations in CF children remains an open question, but this study gives researchers a mechanistically specific thread to pull.

Evidence rating

INVESTIGATIONAL — 80/100

Caveats:

• The competition experiments were conducted in vitro and do not confirm that colibactin causes the same effects inside a living gut.
• Metagenomics and prodrug quantification show gene presence and a chemical precursor, not confirmed colibactin activity or genotoxicity in vivo.
• Only four bacterial species were tested; effects on the broader microbial community remain unknown.
• No funding source was declared by the authors.
• This is a single study and has not yet been independently replicated.

This study combines in vitro co-culture experiments, UPLC-MS/MS metabolite quantification, transposon mutagenesis, and analysis of public stool metagenomes from 208 CF and 2,560 non-CF children. The mechanistic findings are derived from controlled laboratory conditions that do not fully replicate the living gut, and metagenomic gene abundance confirms presence of colibactin biosynthesis capacity but cannot establish in vivo genotoxic activity. The work is a single study and has not yet been independently replicated in a clinical or in vivo setting.